Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Home Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)

/ Publications

Share the Post

About the Author

webmaster

Related Posts

Analysis of inactivating TSC1 and TSC2 alterations in a real-world patient population with advanced gynecological cancers in the Foundation Medicine genomic database
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Evaluation of nab-Sirolimus in Combination With PI3K Pathway Inhibitors to Overcome PI3K/mTOR A117Resistance in PI3K-Mutant Breast Cancer Cell Lines
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
PRECISION 1: A phase 2, multicenter, open-label tumor-agnostic trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors

Comments

Comments are closed.